Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
McKinsey
QuintilesIMS
Novartis
Johnson and Johnson
Merck
Baxter
Chinese Patent Office
Chubb
Boehringer Ingelheim

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,012,437

« Back to Dashboard

Which drugs does patent 9,012,437 protect, and when does it expire?

Patent 9,012,437 protects OZURDEX and is included in one NDA.

This patent has sixteen patent family members in twelve countries.
Summary for Patent: 9,012,437
Title:Implants and methods for treating inflammation-mediated conditions of the eye
Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.
Inventor(s): Wong; Vernon G. (Menlo Park, CA), Hu; Mae W. L. (Los Altos, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/886,465
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 9,012,437

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MACULAR EDEMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,012,437

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,726,918 Methods for treating inflammation-mediated conditions of the eye ➤ Sign Up
9,775,849 Implants and methods for treating inflammation-mediated conditions of the eye ➤ Sign Up
8,063,031 Implants and methods for treating inflammation-mediated conditions of the eye ➤ Sign Up
8,242,099 Implants and methods for treating inflammation-mediated conditions of the eye ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,012,437

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark 1296645 ➤ Sign Up
Australia 7316601 ➤ Sign Up
Australia 2001273166 ➤ Sign Up
Australia 2005246995 ➤ Sign Up
Brazil 0112361 ➤ Sign Up
Canada 2414680 ➤ Sign Up
Germany 60123055 ➤ Sign Up
European Patent Office 1296645 ➤ Sign Up
European Patent Office 1637126 ➤ Sign Up
European Patent Office 3167872 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Deloitte
QuintilesIMS
Farmers Insurance
Baxter
Cerilliant
Daiichi Sankyo
Fish and Richardson
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot